News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alimera Sciences (ALIM) Reports Second Quarter 2017 Financial Results



8/3/2017 1:34:37 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
ATLANTA, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced top-line financial results for the three months ended June 30, 2017.

“We are very pleased that in the second quarter of 2017 we achieved positive adjusted EBITDA for the first time in the history of the Company”, said Dan Myers, Alimera's Chief Executive Officer. “We accomplished this through revenue growth of 8% compared to the same period in 2016 while establishing an appropriate level of operating expenses following the U.S. launch. Additionally, we amended our agreement with pSivida in July to allow for the potential expansion of ILUVIEN’s indication to include posterior uveitis in Europe, the Middle East and Africa.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES